LCN2 and pancreatic neoplasm: An orthotopic xenograft mouse model of pancreatic cancer showed a decrease in tumor size, metastatic score, and the expression of the CD31 angiogenesis marker in the LCN2-overexpressing mice group compared to the control group (non-LCN2-expressing pancreatic cancer cells) [50].